Martyna Kubisztal

Martyna Kubisztal

Auto-generated profile, based on publicly available information

Martyna Kubisztal


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
BMBrian Maloney
Brian Maloney
MKMartyna Kubisztal
Martyna Kubisztal
ZGZiqian Ge
Ziqian Ge
YLYin Lu
Yin Lu
LSLisa Strotmann
Lisa Strotmann
RPRichard Kevin Porter
Richard Kevin Porter
Oral squamous cell carcinoma (OSCC) is major cause of human cancer. The enzyme, nicotinamide N-methyltransferase (NNMT) is overexpressed in a variety of human cancers including OSCC. Our laboratory identified two small molecule inhibitors of NNMT (AG-670 and AO-022) based on a pharmacophore of the in silico nicotinamide binding site. These inhibitors were demonstrated to inhibit the isolated NNMT enzyme with EC50 values in the micromolar range. Using an oral squamous cancer cell line as a model, it was demonstrated that NNMT is expressed in SCC-4 cells, but not MCF 7 cells, and that the inhibitors were cytotoxic to SCC-4 cells (IC50 values in the micromolar range). In an endeavour to investigate the mechanism behind their lethality, sub-lethal doses of the inhibitors were demonstrated to inhibit in situ mitochondrial oxygen consumption in SCC-4 cells but not in MCF 7 cells. It was further demonstrated that the NNMT inhibitors did not directly inhibit mitochondrial electron transport chain activity. Thus, we can deduce that the NNMT inhibitors effect mitochondrial activity indirectly via NNMT. We conclude that NNMT is a potential drug target for oral cancer.

22 March 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
BMBrian Maloney
Brian Maloney
MKMartyna Kubisztal
Martyna Kubisztal
ZGZiqian Ge
Ziqian Ge
YLYin Lu
Yin Lu
LSLisa Strotmann
Lisa Strotmann
RPRichard Kevin Porter
Richard Kevin Porter
Background/Objectives: Oral squamous cell carcinoma (OSCC) is a major cause of human cancer. The enzyme, nicotinamide N-methyltransferase (NNMT), is overexpressed in a variety of human cancers, including OSCC. Our objective was to target NNMT with novel inhibitors and determine their anti-cancer efficacy while shedding light on their possible mechanism of action. Methods: We identified two small molecule inhibitors of NNMT (AG-670 and AO-022) based on a pharmacophore of the in silico nicotinamide binding site. These inhibitors were investigated for (i) potency to inhibit the activity of the isolated NNMT enzyme (EC50 values), (ii) cytotoxicity (IC50 values) against the human OSCC cell line, SCC-4, and (iii) ability to affect cellular energy metabolism, as measured by oxygen consumption, in SCC-4 cells (plus dysplastic oral keratinocytes (DOK) cells and breast cancer MCF-7 cells). Immunoblotting was used to determine whether NNMT was expressed in the aforementioned cells. Results: NNMT is expressed in SCC-4 and DOK cells (and primary human oral keratinocytes) but not MCF 7 cells. The NNMT inhibitors inhibit isolated NNMT enzyme activity and were cytotoxic to SCC-4 cells (EC50 and IC50 values in the micromolar range). Sublethal doses of the inhibitors were demonstrated to inhibit in situ mitochondrial oxygen consumption in SCC-4 and DOK cells but not in MCF-7 cells. It was demonstrated that the NNMT inhibitors do not directly inhibit mitochondrial electron transport chain activity. Thus, we deduce that the NNMT inhibitors affect mitochondrial activity indirectly via NNMT. Conclusions: It is concluded that NNMT is a potential drug target for oral cancer.